惠泰医疗：拟斥资1.5亿至2亿元回购股份 用于员工激励

Core Viewpoint - The company Huatai Medical (688617) announced a share buyback plan to enhance investor confidence and establish a long-term incentive mechanism, with a total buyback amount between 150 million and 200 million yuan, at a maximum price of 315 yuan per share [1] Group 1: Buyback Plan - The buyback will be conducted through centralized bidding and is expected to occur within 10 months from the board's approval [1] - The estimated number of shares to be repurchased ranges from 476,200 to 634,900, representing 0.34% to 0.45% of the company's total share capital [1] - The company stated that the buyback will not significantly impact its daily operations, finances, research and development, or future growth [1] Group 2: Company Performance - Huatai Medical specializes in the research, production, and sales of electrophysiological and interventional medical devices, focusing on coronary pathways and cardiac electrophysiology [1] - For the first three quarters of 2025, the company reported total operating revenue of 1.867 billion yuan, a year-on-year increase of 22.47%, and a net profit attributable to shareholders of 623 million yuan, up 18.02% year-on-year [1]